期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HER2阴性转移性乳腺癌病人二线治疗的有效性和安全性评估:RIBBON-2

RIBBON-2:Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for SecondLine Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
下载PDF
导出
摘要 3背景 ·转移性乳腺癌（metastatic breast cancer，MBC）病人的一线治疗中，此前的3个Ⅲ期临床试验（E2100、AVADO和RIBBON-1）已经证实，贝伐单抗联合多种化疗药物，都可以提高患者的无进展生存率（progression-free survival，PFS）。 <正>1文献来源Brufsky AM,Hurvitz S,Perez E,et al.RIBBON-2:A randomized,double-blind,placebo-controlled,phaseⅢtrial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor2-negative metastatic breast cancer[J].J Clin Oncol,2011,29(32):4286-4293.2
作者 王晓稼 钱学珂
机构地区 浙江省肿瘤医院乳腺外科 汕头大学医学院 广东省人民医院肿瘤中心
出处 《循证医学》 CSCD 2012年第3期153-156,共4页 The Journal of Evidence-Based Medicine
关键词 乳腺肿瘤 临床试验 Ⅲ期 贝伐单抗 转移 性乳腺癌 人表皮生长因子受体-2 breast neoplasms clinical trial, phase Ⅲ Bevacizumab metastatic breast cancer human epidermalgrowth receptor-2
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Miller K, Wang M, Gralow J, et al. Paclitaxel plus Bevacizumab versus Paclitaxel alone for metastatic breast cancer [J]. N Engl J Med, 2007,357 (26) : 2666-2676.
  • 2Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: A phase Ⅲ trial of Bevacizumah plus Paclitaxel versus Paclitaxel in women with metastatic breast cancer [J]. J Clin Oneol, 2009,27 (30) : 4966-4972.
  • 3Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of Bevacizumab plus Docetaxel compared with placebo plus Docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2010,28(20) : 3239-3247.
  • 4Robert N J, Die' ras V, Glaspy J, et al. RIBBON-I: Randomized, double-blind, placebo-controlled, phase Ⅲ trim of chemotherapy with or without Bevacizumab for first-line treatment of human epidermal growth factor receptor 2- negative, locally recurrent or metastatic breast cancer [J]. J Clin Oncol, 2011,29(10) : 1252-1260.
  • 5Miller KD, Chap LI, Holmes FA, et al. Randomized phase Ⅲ trial of Capecitabine compared with Bevacizumab plus Capecitabine in patients with previously treated metastatic breast cancer[J ]. J Clin Oncol, 2005,23 (4):792-799.
  • 6yon Minckwitz G, Eidtmann H, Rezai M, et,al.Neoadjuvant chemotherapy and Bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012,366(4):299-309.
  • 7Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer [J]. N Engl J Med, 2012,366(4) :310-320.
循证医学
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部